| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/03/2007 | US20070098709 Methods for treating and preventing diabetic retinopathy |
| 05/03/2007 | US20070098708 Heparan sulfate glycosaminoglycan lyase and uses thereof |
| 05/03/2007 | US20070098707 Methods and Compositions for Inhibiting C-MET Dimerization and Activation |
| 05/03/2007 | US20070098706 Polypeptide includes an NADPH oxidase cytosolic cofactor polypeptide NOXA1 or p67phox having a C-terminal SH3 domain insertion mutation of at least three consecutive amino acids positioned so as to reduce activity of the purified polypeptide relative to the wild-type cofactor polypeptide |
| 05/03/2007 | US20070098691 Binding site amino acid sequences for use as targeting agents in immunotherapeutics; antitumor agents; which conforms to human leukocyte antigen (HLA) motifs; immunogens; cytotoxic T lymphocytes; comprises proteases; prostate cancer |
| 05/03/2007 | US20070098690 Truncated CMV promoters and vectors containing same |
| 05/03/2007 | US20070098688 Polymer conjugates of interferon beta-1a and uses |
| 05/03/2007 | US20070098687 Pharmaceutical composition containing interferon for the treatment of hpv infections |
| 05/03/2007 | US20070098686 Use of apoptotic cells ex vivo to generate regulatory T Cells |
| 05/03/2007 | US20070098685 Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
| 05/03/2007 | US20070098684 Methods of reducing aggregation of IL-1ra |
| 05/03/2007 | US20070098683 antiproliferative agents; interleukins, immunoglobulins, colony stimulating factors |
| 05/03/2007 | US20070098682 Cytokine zalpha11 ligand antibodies |
| 05/03/2007 | US20070098681 Apo-2 ligand/trail variants and uses thereof |
| 05/03/2007 | US20070098680 Agent for treating diabetes mellitus |
| 05/03/2007 | US20070098677 Ophthalmic compositions containing galactomannan polymers and borate |
| 05/03/2007 | US20070098635 Secreted polypeptide species associatedwith cardiovascular disorders |
| 05/03/2007 | US20070098634 method of inhibiting the growth; inhibiting neoplastic cell growth; cancer |
| 05/03/2007 | DE10333509B4 Gegen VEGF gerichtete Erkennungsmoleküle und die Verwendung dieser Directed against VEGF recognition molecules and the use of these |
| 05/03/2007 | DE10158036B4 Antiallergisches Mittel und dessen Verwendung Anti-allergic agent and its use |
| 05/03/2007 | DE10065704B4 Verwendung einer Kombination aus Proteasen und einer Retinol-Quelle zur Bekämpfung der Hautalterung Using a combination of proteases and a retinol-source to combat skin aging |
| 05/03/2007 | CA2665717A1 Methods and compositions comprising a flightless i antagonist for modulating wound repair |
| 05/03/2007 | CA2627716A1 Selective vpac2 receptor peptide agonists |
| 05/03/2007 | CA2627543A1 Implantable biocompatible immttnoisolatory vehicle for delivery of gdnf |
| 05/03/2007 | CA2627485A1 Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein |
| 05/03/2007 | CA2627478A1 Therapeutic method for blood coagulation disorder |
| 05/03/2007 | CA2627457A1 Botulinum neurotoxin a protein receptor and uses thereof |
| 05/03/2007 | CA2627336A1 Method of modulation of mullerian inhibitory substance (mis) receptor for the treatment of neurodegenerative diseases. |
| 05/03/2007 | CA2627309A1 Pseudomonas aeruginosa outer membrane protein pa5158 |
| 05/03/2007 | CA2627298A1 Use of tgf-.beta.1 inhibitor peptides in the preparation of an immune response modulating agent |
| 05/03/2007 | CA2626392A1 In vivo detection of apoptosis |
| 05/03/2007 | CA2626152A1 Methods of specifying mesodermal, endodermal and mesoendodermal cell fates |
| 05/03/2007 | CA2625646A1 Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
| 05/03/2007 | CA2525255A1 Minimalist bzip proteins and uses thereof |
| 05/02/2007 | EP1780279A1 Fabrication of beta-pleated sheet proteins with specific binding properties |
| 05/02/2007 | EP1780278A2 Mammalian calcium channels and related probes, cell lines and methods |
| 05/02/2007 | EP1780277A1 IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons |
| 05/02/2007 | EP1780276A1 Bone/joint disease sensitivity gene and use thereof |
| 05/02/2007 | EP1780270A1 A detoxifizyme having activity of transforming aflatoxin and the gene encodes thereof |
| 05/02/2007 | EP1780268A2 PSCA: Prostate stem cell antigen and uses thereof |
| 05/02/2007 | EP1780264A2 Nucleic acid nematicides |
| 05/02/2007 | EP1780219A2 Protein S polypeptides and uses thereof |
| 05/02/2007 | EP1779865A1 Use of human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 05/02/2007 | EP1779864A1 Pth-containing preparation for transmucosal administration |
| 05/02/2007 | EP1779863A1 Use of TGF-Beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
| 05/02/2007 | EP1779862A1 Erythropoietin for stimulating endothelial progenitor cells |
| 05/02/2007 | EP1779861A1 Use of nerve growth factor (NGF) for the preparation of a medicament for the stimulation of weight loss |
| 05/02/2007 | EP1779860A2 The chromatin peptides blocking human HIF-1a gene and modulating the downstream related genes |
| 05/02/2007 | EP1779859A2 Use of depsipeptide and congeners thereof as immunosuppressants in preventing or treating rejection following transplantation and for induction of apoptosis of activated CD4 or CD8 T-cells |
| 05/02/2007 | EP1779849A1 V-ATPase inhibitors for the treatment of septic shock |
| 05/02/2007 | EP1779848A1 V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| 05/02/2007 | EP1778875A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 05/02/2007 | EP1778849A1 Synthesis of spider dragline and/or flagelliform proteins |
| 05/02/2007 | EP1778724A2 Antiangiogenic peptides |
| 05/02/2007 | EP1778722A1 Proteins of natural origin and materials made therefrom |
| 05/02/2007 | EP1778720A2 Antimicrobial peptides comprising an arginine- and/or lysine-containing motif |
| 05/02/2007 | EP1778718A1 Inhibitors of iap |
| 05/02/2007 | EP1778360A2 Compositions and methods for viscosupplementation |
| 05/02/2007 | EP1778308A2 Amphipathic proteinaceous coating on nanoporous polymer |
| 05/02/2007 | EP1778290A1 Use of glycerol dipalmitostearate for improving the bioavailability of protein active ingredients in subcutaneous or intramuscular injectable formulations |
| 05/02/2007 | EP1778282A1 Mutated hiv nef for modulating immunity |
| 05/02/2007 | EP1778279A1 Pharmaceutical composition containing botulinum neurotoxin a2 |
| 05/02/2007 | EP1778278A2 Gonadotropin releasing hormone antagonists |
| 05/02/2007 | EP1778277A2 C-terminally truncated interferon |
| 05/02/2007 | EP1778276A1 Tnf-binding protein-1 in the treatment of psoriasis |
| 05/02/2007 | EP1778275A2 Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| 05/02/2007 | EP1778274A2 Modulation of fiaf and the gastrointestinal microbiota |
| 05/02/2007 | EP1778273A2 Promotion of axonal regeneration |
| 05/02/2007 | EP1778272A1 Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) |
| 05/02/2007 | EP1778271A2 Peptides for the treatment of herpes virus infections |
| 05/02/2007 | EP1778268A1 Treatment of renal dysfunction and multiple myeloma using pacap compounds |
| 05/02/2007 | EP1778267A2 Compositions and methods related to heart failure |
| 05/02/2007 | EP1778266A2 Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| 05/02/2007 | EP1778265A2 Guanylhydrazone compounds, compositions, methods of making and using |
| 05/02/2007 | EP1778264A2 Tie receptor and tie ligand materials and methods for modulating female fertility |
| 05/02/2007 | EP1778203A2 Apparatus and method for transdermal delivery of natriuretic peptides |
| 05/02/2007 | EP1778184A1 Stable suspension formulations of erythropoietin receptor agonists |
| 05/02/2007 | EP1673105B1 Use of follicle stimulating hormone for reduction of spermatozoa chromosomal aberration in males |
| 05/02/2007 | EP1644509B1 Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis |
| 05/02/2007 | EP1539213B1 Cardioprotective therapies based on enzymatic elimination of lipid peroxides by allene oxide synthase |
| 05/02/2007 | EP1488801B1 Chemical igf-i composition for the treatment and prevention of neurodegenerative diseases |
| 05/02/2007 | EP1471871B1 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 05/02/2007 | EP1418933B1 Process for preparing glycopeptide phosphonate derivatives |
| 05/02/2007 | EP1395606B1 Pyrrolidin-2-one derivatives as inhibitors of factor xa |
| 05/02/2007 | EP1365797B1 Antibodies modulating the upa/upar interaction and uses thereof |
| 05/02/2007 | EP1346058B1 Adenoviral systems and the uses thereof |
| 05/02/2007 | EP1282725B1 METHODS OF MODULATING FUNCTIONS OF POLYPEPTIDE GalNAc TRANSFERASES AND OF SCREENING SUBSTANCES THEREFOR |
| 05/02/2007 | EP1280826B1 Polypeptides for inhibiting april-mediated b- and t-cell proliferation. |
| 05/02/2007 | EP1261372B1 Method of treating cancer with anti-neurotrophin agents |
| 05/02/2007 | EP1255769B1 Universal procedure for refolding recombinant proteins |
| 05/02/2007 | EP1220830B1 Use of elastase for opening obstructed arteries and veins |
| 05/02/2007 | EP1156821B1 Treatment of infertility |
| 05/02/2007 | EP1104323A4 Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
| 05/02/2007 | EP1077721B1 Prevention and treatment of hypergastrinemia |
| 05/02/2007 | EP1077069B1 Preventives/remedies for hepatic cirrhosis |
| 05/02/2007 | EP1032596B1 Lactalbumin production process |
| 05/02/2007 | EP1004313B1 Cachexia remedy |
| 05/02/2007 | EP0998305B1 Cytolysis of target cells by superantigen conjugates inducing t-cell activation |
| 05/02/2007 | EP0953047B1 Vaccine containing a peroxiredoxin |
| 05/02/2007 | EP0906426B1 Antibodies to the ed-b domain of fibronectin, their construction and uses |